Where Research
Meets Technology
Mission
To empower ATMP manufacturers to accelerate the development of innovative cellular therapies, ensuring more efficient, controlled, reliable, and high-quality outcomes, through cutting-edge automated systems and fully dedicated customer support.
Vision
To drive the global market toward automated solutions for cell cultures, leading innovation in advanced therapies and making next-generation cell production more efficient, safe, reliable, and accessible to the ATMP industry.
VivaBioCell was born in 2004 as a spin-off of the University of Udine, with the visionary idea of prompting innovation in the field of cell culturing.
The challenge to improve and increase the cell therapy manufacturing scale led to the development of the NANT XL System, launched on the market in 2019. In 2021 VivaBioCell released NANT Maestro, the first stand-alone software designed to create and manage cell culture protocols and users for NANT XL System.
In 2024, through strategic collaborations with selected lead users, VivaBioCell developed NANT XL PLUS System, our flagship solution. This synergistic approach ensured that, upon market entry, the product was fully ready to use, perfectly perfectly honed and aligned with the highest standards of performance and quality.
At the beginning of 2026 the NANT Maestro On Premises software has been released, which allows the simultaneous of multiple NANT XL PLUS Bioreactors simultanously.
ImmunityBio Inc.
VivaBioCell is fully owned by ImmunityBio Inc. (formerly NantKwest, Inc.) a subsidiary of NantWorks LLC group (Culver City, California), an ecosystem of companies focused on biotech, healthcare AI, and mobility.
ImmunityBio is focused on developing next-generation cell and immunotherapy solutions intended to eradicate cancer and infectious disease by strengthening the patient’s immune system. Founded in 2014 by Dr. Patrick Soon-Shiong, who has devoted his life to study the mechanisms that enable the immune system to recognize and attack tumors, ImmunityBio is now a clinical-stage biotechnology company with 27 clinical trials—18 of which are in Phase 2 or 3 development—across 13 indications in liquid and solid tumors.
VivaBioCell and ImmunityBio closely cooperate to improve the current state-of-the-art of cell therapy manufacturing by developing new and innovative tools that will change the way we look at these technologies today.
